JPWO2020190977A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020190977A5 JPWO2020190977A5 JP2021555607A JP2021555607A JPWO2020190977A5 JP WO2020190977 A5 JPWO2020190977 A5 JP WO2020190977A5 JP 2021555607 A JP2021555607 A JP 2021555607A JP 2021555607 A JP2021555607 A JP 2021555607A JP WO2020190977 A5 JPWO2020190977 A5 JP WO2020190977A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- treatment
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819642P | 2019-03-17 | 2019-03-17 | |
| US62/819,642 | 2019-03-17 | ||
| US201962819725P | 2019-03-18 | 2019-03-18 | |
| US62/819,725 | 2019-03-18 | ||
| PCT/US2020/023215 WO2020190977A1 (en) | 2019-03-17 | 2020-03-17 | Treatment of cancers using sephb4-hsa fusion proteins |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525223A JP2022525223A (ja) | 2022-05-11 |
| JP2022525223A5 JP2022525223A5 (https=) | 2023-04-03 |
| JPWO2020190977A5 true JPWO2020190977A5 (https=) | 2023-04-03 |
| JP7809324B2 JP7809324B2 (ja) | 2026-02-02 |
Family
ID=72520496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555607A Active JP7809324B2 (ja) | 2019-03-17 | 2020-03-17 | ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220249621A1 (https=) |
| EP (1) | EP3941512A4 (https=) |
| JP (1) | JP7809324B2 (https=) |
| KR (1) | KR20220015375A (https=) |
| CN (1) | CN113939309A (https=) |
| AU (1) | AU2020241963A1 (https=) |
| CA (1) | CA3133437A1 (https=) |
| WO (1) | WO2020190977A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3139416A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
| EP4168019A4 (en) * | 2020-06-17 | 2024-07-31 | 4C Biomed Services Ltd. | ANTIBODIES AGAINST EPHB2 AND ITS USE IN COMBINATION THERAPY |
| KR20230106607A (ko) * | 2020-10-11 | 2023-07-13 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법 |
| CA3211742A1 (en) * | 2021-03-18 | 2022-09-22 | Valery Krasnoperov | Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment |
| US20250123284A1 (en) * | 2021-09-07 | 2025-04-17 | Vasgene Therapeutics Inc | Diagnostic methods for cancer using ephrinb2 expression |
| WO2023154948A1 (en) * | 2022-02-14 | 2023-08-17 | Vasgene Therapeutics Inc. | Ephrin type-b receptor 4 (ephb4) agents and production thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2703136A1 (en) | 2007-03-12 | 2008-09-18 | Vasgene Therapeutics, Inc. | Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer |
| CA3139416A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
-
2020
- 2020-03-17 WO PCT/US2020/023215 patent/WO2020190977A1/en not_active Ceased
- 2020-03-17 AU AU2020241963A patent/AU2020241963A1/en active Pending
- 2020-03-17 EP EP20772615.9A patent/EP3941512A4/en active Pending
- 2020-03-17 JP JP2021555607A patent/JP7809324B2/ja active Active
- 2020-03-17 KR KR1020217033333A patent/KR20220015375A/ko active Pending
- 2020-03-17 CN CN202080036834.1A patent/CN113939309A/zh active Pending
- 2020-03-17 US US17/439,926 patent/US20220249621A1/en active Pending
- 2020-03-17 CA CA3133437A patent/CA3133437A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7542870B2 (ja) | 免疫療法のためのナノ粒子組成物及び方法 | |
| Zhang et al. | Toripalimab: the first domestic anti-tumor PD-1 antibody in China | |
| JP7227290B2 (ja) | キメラ抗原受容体、組成物及び方法 | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| JP6974311B2 (ja) | 新規ｐｄ−１免疫調節剤 | |
| WO2018187791A1 (en) | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods | |
| JP2020504147A (ja) | Ｐｓｇｌ−１アンタゴニスト及びその使用 | |
| US20240197931A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| JP6566938B2 (ja) | 免疫療法のための組成物及び方法 | |
| JP2020516681A5 (https=) | ||
| US20020155109A1 (en) | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 | |
| AU2016274897B2 (en) | Focused interferon immunotherapy for treatment of cancer | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| JP2023513896A (ja) | 療法において使用するための抗体 | |
| JP2021167324A5 (https=) | ||
| Chen et al. | IL-21-and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma | |
| JP2023520587A (ja) | 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト | |
| Green et al. | Emerging immune checkpoint inhibitors for the treatment of head and neck cancers | |
| JPWO2020190977A5 (https=) | ||
| Glitza Oliva et al. | Immunotherapy for melanoma | |
| CN118373896B (zh) | 抗pd-1抗体与il-2突变体的双功能融合蛋白 | |
| Schwartz et al. | 4-1BB Antibodies in Oncology Clinical Trials: A Review | |
| JPWO2020168110A5 (https=) | ||
| Puca et al. | The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer | |
| JPWO2022198001A5 (https=) |